Infectious Diseases News and Research RSS Feed - Infectious Diseases News and Research

Experimental Ebola treatments to be trialled in West Africa next month

Experimental Ebola treatments to be trialled in West Africa next month

Médecins Sans Frontières/Doctors without Borders (MSF) have announced that three trials of Ebola therapies will begin in West Africa this December. [More]
Searching online for diagnosis before visiting doctor can predict dengue fever outbreaks in China

Searching online for diagnosis before visiting doctor can predict dengue fever outbreaks in China

Queensland University of Technology researchers have found the habit of Googling for an online diagnosis before visiting the doctor can be a powerful predictor of infectious diseases outbreaks. [More]
Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Researchers from Rhode Island and The Miriam hospitals and the Stanford University School of Medicine have found that prescription opioids, including methadone, were involved in 67.8 percent of (or over 135,971 visits to) nationwide emergency department (ED) visits in 2010, with the highest proportion of opioid overdoses occurring in the South. [More]
Research opens new potential target against enterics

Research opens new potential target against enterics

In research published in Nature Chemical Biology, scientists from RIKEN in Japan have discovered a surprisingly simple mechanism through which enterics can adjust to the very different oxygen environments inside the human gut and outside. [More]
Successful treatments help HIV-infected persons achieve similar longevity as those without HIV

Successful treatments help HIV-infected persons achieve similar longevity as those without HIV

New research from the Johns Hopkins Bloomberg School of Public Health suggests that HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV. [More]
UW SMPH awarded $70 million grant to continue work on Inner-City Asthma Consortium

UW SMPH awarded $70 million grant to continue work on Inner-City Asthma Consortium

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded the University of Wisconsin School of Medicine and Public Health a seven-year, $70 million grant for its continuing work on the Inner-City Asthma Consortium (ICAC) -- a nationwide clinical research network to evaluate and develop promising new immune-based treatments. [More]
Survey: Majority of U.S. adult women do not believe that they are up to date on vaccinations

Survey: Majority of U.S. adult women do not believe that they are up to date on vaccinations

A national survey from Rite Aid and National Foundation for Infectious Diseases reveals that the majority of adult women living in the United States do not believe they are up to date on vaccinations to protect against many preventable diseases. [More]
Child-mortality gap narrows between the poorest and wealthiest families in developing countries

Child-mortality gap narrows between the poorest and wealthiest families in developing countries

The child-mortality gap has narrowed between the poorest and wealthiest households in a majority of more than 50 developing countries, a new study from the Stanford University School of Medicine has found. [More]
Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014. [More]
Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash. [More]
Salk Institute researchers heal injured hearts of living mice

Salk Institute researchers heal injured hearts of living mice

Researchers at the Salk Institute have healed injured hearts of living mice by reactivating long dormant molecular machinery found in the animals' cells, a finding that could help pave the way to new therapies for heart disorders in humans. [More]
Study highlights connections between climate change and new outbreak of diseases

Study highlights connections between climate change and new outbreak of diseases

Climate change may affect human health directly or indirectly. In addition to increased threats of storms, flooding, droughts, and heat waves, other health risks are being identified. In particular, new diseases are appearing, caused by infectious agents (viruses, bacteria, parasites) heretofore unknown or that are changing, especially under the effect of changes in the climate (change of host, vector, pathogenicity, or strain). [More]
Study: Preclinical oncology course may increase number of students entering the field

Study: Preclinical oncology course may increase number of students entering the field

With the world facing a shortage of oncologists, Ben-Gurion University of the Negev researchers have determined that preclinical study of oncology may increase the number of students entering the field and may make them more empathetic and concerned about ethical issues of treatment. [More]
LA BioMed to receive Phase II funding through Grand Challenges Explorations

LA BioMed to receive Phase II funding through Grand Challenges Explorations

Los Angeles Biomedical Research Institute announced today that it will receive Phase II funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables individuals worldwide to test bold ideas to address persistent health and development challenges. [More]
Precision awarded $28 million contract to provide management of disease-study specimens for NIAID

Precision awarded $28 million contract to provide management of disease-study specimens for NIAID

Precision for Medicine announced today that its subsidiary, Precision Bioservices, Inc., has been awarded a 7-year contract of up to $28 million to provide management and oversight of disease-study specimens for the National Institute of Allergy and Infectious Diseases. [More]
Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Ruthigen, Inc., announced today enrollment of the first patient in a Randomized, Double-Blind Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery. [More]
Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer. [More]
BD reports quarterly revenues of $2.202B for Q4 2014, provides fiscal 2015 outlook

BD reports quarterly revenues of $2.202B for Q4 2014, provides fiscal 2015 outlook

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.202 billion for the fourth fiscal quarter ended September 30, 2014, representing an increase of 4.8 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis. [More]
FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. [More]
Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas announced today that the U.S. Food and Drug Administration has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis. [More]